Interferons at age 50: Past, current and future impact on biomedicine

Nature Reviews Drug Discovery

Volumn 6, Issue 12, 2007, Pages 975-990

  Borden, Ernest C ^a   Sen, Ganes C ^a   Uze, Gilles ^b   Silverman, Robert H ^a   Ransohoff, Richard M ^a   Foster, Graham R ^c   Stark, George R ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CNRS   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA2 INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; BETA INTERFERON RECEPTOR; BETA1A INTERFERON; FOCAL ADHESION KINASE 1; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; IMATINIB; IMIQUIMOD; INTERFERON; INTERFERON BETA SERINE; INTERFERON RECEPTOR; JANUS KINASE 1; OLIGONUCLEOTIDE; PLACEBO; POLYRIBONUCLEOTIDE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERFERON; RESIQUIMOD; RIBAVIRIN; TOLL LIKE RECEPTOR; UNINDEXED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOMEDICINE; CHILL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA VIRUS; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FATIGUE; GENETIC TRANSCRIPTION; GRANULOCYTOPENIA; HEPATITIS B; HEPATITIS C; HUMAN; INNATE IMMUNITY; MALAISE; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RNA VIRUS; SIDE EFFECT; SIGNAL TRANSDUCTION; TACHYPHYLAXIS; VERRUCA VULGARIS;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; HUMANS; INTERFERONS;

EID: 36749069393     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2422     Document Type: Review

References (278)

1. Isaacs, A. & Lindenmann, J. Virus interference. 1. The interferon. Proc. R. Soc. Land., B, Biol. Sci. 147 258-267 (1957).
2. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
3. Field, A. K., Tytell, A. A., Lampson, G. P. & Hilleman, M. R. Inducers of interferon and host resistance. II, Multistranded synthetic polynucleotide complexes. Proc. Natl Acad. Sci. USA 58, 1004-1010 (1967).
4. Sen, G. C. & Sarkar, S. N. Transcriptional signaling by double-strancled RNA: Role of TLR3. Cytokine Growth Factor Rev. 16, 1-14 (2005).
5. Yoneyama, M. et al. The RNA helicase RIG-1 has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730-737(2004).
6. Tabeta, K. et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl Acad. Sci. USA 101, 3516-3521 (2004).
7. Kato, H. et al. Differential roles of MDA5 and RIG-1 helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
8. Gitlin, L. et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:pOlyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103, 8459-8464 (2006).
9. Le Goffic, R. et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2, e53 (2006).
10. Wang, T. et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nature Med. 10, 1366-1373 (2004).
11. Meylan, E, & Tschopp, J. Toll-like receptors and RNA helicases: Two parallel ways to trigger antiviral responses, Mol. Cell 22, 561-569 (2006).
12. Kawai, T. & Akira, S. Antiviral signaling through pattern recognition receptors. J. Biochem. (Tokyo) 141, 137-145 (2007).
13. Yoneyama, M. & Fujita, T. Cytoplasmic double- stranded DNA sensor. Nature Immunol. 8, 907-908 (2007).
14. Panne, D., Maniatis, T. & Harrison, S. C. An atomic model of the interferon-β enhanceosome. Cell 129, 1111-1123 (2007).
15. Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349-360 (2006).
16. Tenoever, B. R. et al. Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. Science 315, 1274-1278 (2007).
17. Fitzgerald, K. A. et al. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunol. 4, 491-496 (2003).
18. Biron, C. A. & Sen, G. C. in Fields Virology (eds Knipe, D. M. et al.) 249-278 (Lippincott, Williams & Wilkins, Philadelphia, 2006).
19. Hiscott, J., Nguyen, T-L. A., Arguello, M., Nakhaei, P. & Paz, S. Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses. Oncogene 25, 6844-6867 (2006).
20. Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986-2991 (2005).
21. Garcia-Sastre, A. & Biron, C. A. Type 1 interferons and the virus-host relationship: A lesson in detente. Science 312, 879-882 (2006).
22. Finlay, B. B. & McFadden, G. Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens. Cell 124, 767-782 (2006).
23. Pichlmair, A. et al. RIG-1 mediated antiviral responses to single-stranded RNA bearing 5′ phosphates. Science 314, 997-1001 (2006).
24. Casrouge, A. et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314, 308-312 (2006).
25. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
26. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196-200 (2002).
27. Roberts, Z. J. et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1 -IRF-3 signaling axis. J. Exp. Med. 204, 1559-1569 (2007).
28. O'Neill, L. A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Rev. Drug Discov. 5, 549-563 (2006).
29. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discov. 5, 471-484 (2006).
30. Havell, E. A. et al. Two antigenically distinct species of human interferon. Proc. Natl Acad. Sci. USA 72, 2185-2187 (1975).
31. Streuli, M., Nagata, S. & Weissmann, C. At least three human type α-interferons: Structure of α 2. Science 209, 1343-1347 (1980).
32. Taniguchi, T et al. Human leukocyte and fibroblast interferons are structurally related. Nature 285, 547-549 (1980).
33. Goeddel, D. V. et al. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature 290, 20-26 (1981).
34. Pestka, S., Krause, C. D. & Walter, R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (1998).
35. Hardy, M. R, Owczarek, C. M., Jermiin, L. S., Eideback, M. & Hertzog, P. J. Characterization of the type I interferon locus and identification of novel genes. Genomics 84, 331-345 (2004).
36. Coelho, L. F., de Freitas Almeida, G. M., Mennechet, F. J., Blangy; A. & Uze, G. Interferon-α and -β differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression. Proc. Natl Acad. Sci. USA 102, 11917-11922 (2005).
37. Foster, G. R. et al. IFN-α subtypes differentially affect human T cell motility. J. Immunol. 173, 1663-1670 (2004).
38. Hilkens, C. M., Schlaak, J. F & Kerr, I. M. Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol. 171, 5255-5263 (2003).
39. Uze, G., Schreiber, G., Piehler, J. & Pellegrini, S. The receptor of the type I interferon family. Cur. Topics Microbiol. Immunol. 316 71-95 (2007).
40. Walker, J. & Tough, D. F. Modification of TLR-induced activation of human dendritic cells by type IIFN: Synergistic interaction with TLR4 but not TLR3 agonists. Eur. J. Immunol. 36, 1827-1836 (2006).
41. Roberts, R. M., Liu, L. & Alexenko, A. New and atypical families of type I interferons in mammals: Comparative functions, structures, and evolutionary relationships. Prog. Nucleic Acid Res Mol. Biol. 56, 287-325 (1997).
42. LaFleur. D. W. et al. Interferon-κ, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276, 39765-39771 (2001).
43. Coccia, E. M. et al. Viral infection and Toll-tike receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796-805 (2004).
44. Mitsui, Y. & Senda, T. Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. J. Interferon Cytokine Res. 17, 319-326 (1997).
45. Gavutis, M., Jaks, E., Lamken, P. & Piehler, J. Determination of the two-dimensional interaction rate constants of a cytokine receptor complex. Biophys. J. 90, 3345-3355 (2006).
46. Jaitin, D. A. et al. Inquiring into the differential action of interferons (IFNs): An IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFNI-β. Mol. Cell Biol. 26, 1888-1897 (2006).
47. Jaks, E., Gavutis, M, Uze, G., Martal, J. & Piehler, J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 366, 525-539 (2007).
48. Kalie, E., Jaitin, D. A., Abramovich, R. & Schreiber, G. An interferon α2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 282 11602-11611 (2007).
49. Severa, M. et al. Differential responsiveness to IFN-α and IFN-β of human mature DC through modulation of IFNAR expression. J. Leukoc. Bial. 79, 1286-1294 (2006).
50. Frodsham, A. J. et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl Acad. Sci. USA 103, 9148-9153 (2006).
51. Bach, E. A., Aguet, M. & Schreiber, R. D. The IFN γ receptor: A paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563-591 (1997).
52. Kotenko, S. V & Langer, J. A. Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4, 593-608 (2004).
53. Roesler, J. et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-γ-receptor (IFN-γR1) deficiency: Mutational analysis and evaluation of therapeutic options. Exp. Hematol. 27, 1368-1374 (1999).
54. Uze, G. & Monneron, D. IL-28 and IL-29: Newcomers to the interferon family. Biochimie 89, 729-734 (2007).
55. Zinn, K., DiMaio, D. & Maniatis, T. Identification of two distinct regulatory regions adjacent to the human β-interferon gene. Cell 34, 865-879 (1983).
56. Merlin, G., Chebath, J., Benech, P., Metz, R. & Revel, M. Molecular cloning and sequence of partial cDNA for interferon-induced (2′-5′)oligo(A) synthetase mRNA from human cells. Proc. Natl Acad. Sci. US4 80, 4904-4908 (1983).
57. Friedman, R. L., Manly, S. R, McMahon, M., Kerr, I. M. & Stark, G. R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38, 745-755 (1984).
58. Friedman, R. L. & Stark, G. R. α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 314, 637-639 (1985).
59. Fu, X. Y., Schindler, C., Improta, T, Aebersold, R. & Darnell, J. E. Jr. The proteins of ISGF-3, the interferon α-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl Acad. Sci. USA 89, 7840-7843 (1992).
60. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
61. Schindler, C., Levy, D. E. & Decker, T. JAK-STAT signaling: From interferons to cytokines. J. Biol. Chem. 282, 20059-20063 (2007).
62. Velazquez, L., Fellous, M., Stark, G. R. & Pellegrini, S. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70, 313-322 (1992).
63. Qing, Y. & Stark, G. R. Alternative activation of STAT1 and STAT3 in response to interferon-α. J. Biol. Chem. 279, 41679-41685 (2004).
64. van Boxel-Dezaire, A- H., Rani, M. R. & Stark, G. R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25, 361-372 (2006).
65. van Boxel-Dezaire, A. H. & Stark, G. R. Cell type-specific signaling in response to interferon-γ. Curr. Top. Microbiol. Immunol. 316 119-154 (2007).
66. Jouanguy, E. et al. Human primary immunodeficiencies of type I interferons. Biochimie 89, 878-883 (2007).
67. Rani, M. R., Hibbert, L., Sizemore, N., Stark, G. R. & Ransohoff, R. M. Requirement of phosphoinositide 3-kinase and Akt for interferon-β-mediated induction of the β-R1 (SCYB111) gene. J Biol. Chem. 277, 38456-38461 (2002).
68. Rani, M. R. & Ransohoff, R. M. Alternative and accessory pathways in-the regulation of IFN-β-mediated gene expression. J. Interferon Cytokine Res. 25, 788-798 (2005).
69. Hilkens, C. M., Schlaak, J. F. & Kerr, I. M. Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol. 171, 5255-5263 (2003).
70. Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nature Rev. Immunol. 5, 375-386 (2005).
71. Alexander, W. S. & Hilton, D. J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503-529 (2004).
72. Yi, T. et al. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169, 5978-5985 (2002).
73. Ho, H. H. & Ivashkiv, L. B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281, 14111-14118 (2006).
74. Hu, X. et al. Sensitization of IFN-γ Jak-STAT signaling during macrophage activation. Nature Immunol. 3, 859-866 (2002).
75. Kirkwood, J. et al. Modulation of STAT1 and STAT3 signaling in melanoma by high-dose IFN-α2b. Clin. Cancer Res. 13, 1523-1531 (2007).
76. Kumar, A., Commane, M., Flickinger, T. W., Horvath, C. M. & Stark, G. R. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278, 1630-1632 (1997).
77. Yang, J. et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65, 959-947 (2005).
78. Yang, J. et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev. 21, 1396-1408 (2007).
79. Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon α, * or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623-15628 (1998).
80. de Veer, M. J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69, 912-920 (2001).
81. Silverman, R. H. Viral encounters with OAS and RNase L during the interferon antiviral response. J. Virol. 5 Sep 2007 (doi:10.1128/ JVI.01471-07).
82. Kerr, I. M. & Brown, R. E. pppA2′p5′A2′p5′A: An inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc. Natl Acad. Sci. USA 75, 256-260 (1978).
83. Zhou, A., Hassel, B. A. & Silverman, R. H. Expression cloning of 2-5A-dependent RNAase: A uniquely regulated Mediator of interferon action. Cell 72, 753-765 (1993).
84. Dong, B. & Silverman, R. H. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J. Biol. Chem. 270, 4133-4137 (1995).
85. Wreschner, D. H., McCauley, J. W., Skehel, J. J. & Kerr, I. M. Interferon action - sequence specificity of the ppp(A2′p nA-dependent ribonuclease. Nature 289, 414-417 (1981).
86. Floyd-Smith, G., Slattery; E. & Lengyel, P. Interferon action: RNA cleavage pattern of a (2′-5′)oligoadenylate-dependent endonuclease. Science 212, 1030-1032 (1981).
87. Zhou, A. et al. Interferon action and apoptosis are defective in mice devoid of 2′, 5′-oligoadenylate-dependent RNase, L. EMBO J. 16, 6355-6363 (1997).
88. Castelli, J. C. et al. The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ. 5, 313-320 (1998).
89. Castelli, J. C. et al. A study of the interferon antiviral mechanism: Apoptosis activation by the 2-5A system. J. Exp. Med. 186, 967-972 (1997).
90. Malathi, K., Dong, B., Gale, M. Jr, Silverman, R. H. Small self RNA generates by RNase L amplifies antiviral innate immunity. Nature 448, 816-819 (2007).
91. Thakur, C. S. et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc. Natl Acad. Sci. USA 104, 9585-9590 (2007).
92. Roberts, W. K., Hovanessian, A. Brown, R. E., Clemens, M. J. & Kerr, I. M. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 264, 477-480 (1976).
93. Zilberstein, A., Kimchi, A., Schmidt, A. & Revel, M. Isolation of two interferon-induced translational inhibitors: A protein kinase and an oligo-isoadenylate synthetase, Proc. Natl Acad. Sci. USA 75, 4734-4738 (1978).
94. Meurs, E. et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62, 379-390 (1990).
95. Williams, B. R. Signal integration via PKR. Sci STKE 89, RE2 (2001).
96. Williams, B. R. PKR; a sentinel kinase for cellular stress. Oncogene 18, 6112-6120 (1999).
97. Patel, R. C. & Sen, G. C. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 17, 4379-4390 (1998).
98. Gale, M. Jr. & Katze, M. G. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther. 78, 29-46 (1998).
99. Sarkar, S. N. & Sen, G. C. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol. Ther. 103, 245-259 (2004).
100. Wang, C. et al. α Interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77, 3898-3912 (2003).
101. Lindenmann, J. Inheritance of resistance to influenza virus in mice. Proc. Soc. Exp. Biol. Med. 116, 506-509 (1964).
102. Horisberger, M. A., Staeheli, P. & Haller, O. Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc. Natl Acad. Sci. USA 80, 1910-1914 (1983).
103. Staelheli, P., Haller, O., Boll, W., Lindenmann, J. & Weissmann, C. Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44 147-158 (1986).
104. Haller, O., Staeheli, P. & Kochs, G. Interferon-induced Mx proteins in antiviral host defense. Biochimie 89, 812-818 (2007).
105. Recht, M., Borden, E. C. & Knight, E. Jr. A human 15-kDa IFN-induced protein induces the secretion of IFN-γ. J. Immunol. 147, 2617-2623 (1991).
106. D'Cunha, J. et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 157 4100-4108 (1996).
107. Andersen, J. B. & Hassel, B. A. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe? Cytokine Growth Factor Rev. 17, 411-421 (2006).
108. Okumura, A., Lu, G., Pitha-Rowe, I. & Pitha, P. M. Innate antiviral response targets HIV- 1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl Acad. Sci. USA 103, 1440-1445 (2006).
109. Lenschow, D. J. et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104, 1371-1376 (2007).
110. Zhou, Q. et al. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 272, 18240-18244 (1997).
111. Ben-Efraim, I., Zhou, Q., Wiedmer, T., Gerace, L. & Sims, P. J. Phospholipid scramblase 1 is imported into the nucleus by a receptor-mediated pathway and interacts with DNA. Biochemistry 43, 3518-3526 (2004).
112. Dong, B. et al. Phospholipid scramblase 1 potentiates the antiviral activity of interferon. J. Virol. 78, 8983-8993 (2004).
113. Kayagaki, N. et al. Type I interferons (IFNS) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451-1460 (1999).
114. Chawla-Sarkar, M., Leaman, D. W. & Borden, E. C. Preferential induction of apoptosis by interferon (IFN)-β compared with IFN-α2: Correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer. Res. 7, 1821-1831 (2001).
115. Chen, Q. et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98, 2183-2192 (2001).
116. Kelly, J. M. et al. Characterization of a human gene inducible by α- and β-interferons and its expression in mouse cells. EMBO J. 5, 1601-1606 (1986).
117. Martensen, P. M. & Justesen, J. Small ISCs coming forward. J. Interferon Cytokine Res. 24, 1-19 (2004).
118. Tahara, E. Jr. et al. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol. Immunother. 54, 729-740 (2005).
119. Martensen, P. M. et al. The interferon α induced protein ISG12 is localized to the nuclear membrane. Eur. J. Biochem. 268, 5947-5954 (2001).
120. Labrada, L., Liang, X. H., Zheng, W., Johnston, C. & Levine, B. Age-dependent resistance to lethal alphavirus encephalitis in mice: analysis of gene expression in the central nervous system and identification of a novel interferon-inducible protective gene, mouse ISG12. J. Virol. 76, 11688-11703 (2002).
121. Anderson, S. L., Carton, J. M., Lou, J., Xing, L. & Rubin, B. Y. Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology 256, 8-14 (1999).
122. Espert, L. et al. ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J. Biol. Chem. 278, 16151-16158 (2003).
123. Regad, T. et al. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 20, 3495-3505 (2001).
124. Liu, Y., George, C. X., Patterson, J, B. & Samuel, C. E. Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase. J. Biol. Chem. 272, 4419-4428 (1997).
125. Chin, K. C. & Cresswell, P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc. Natl Acad. Sci. USA 98, 15125-15130 (2001).
126. Melkova, Z. & Esteban, M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 155, 5711-5718 (1995).
127. Enninga, J., Levy, D. E., Blobel, G. & Fontoura, B. M. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 295, 1523-1525 (2002).
128. Samuel CE Antiviral actions of interferons. Clin. Microbial. Rev. 14, 778-809 (2001).
129. Siegal, F P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835-1837 (1999).
130. Zhao, W., Cha, E. N., Lee, C., Park, C. Y. & Schindler, C. Stat2-dependent regulation of MHC class II expression. J. Immunol. 179, 463-471 (2007).
131. Cresswell, P. Intracellular surveillance: Controlling the assembly of MHC class I-peptide complexes. Traffic 1, 301-305 (2000).
132. Drozina, G., Kohoutek, J., Jabrane-Ferrat, N. & Peterlin, B. M. Expression of MHC II genes. Curr. Top. Microbiol. Immunol. 290 147-170 (2005).
133. Fruh, K. & Yang, Y. Antigen presentation by MHC class I and its regulation by interferon γ. Curr. Opin. Immunol. 11, 76-81 (1999).
134. Gaczynska, M., Rock, K. L. & Goldberg, A. L. γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264-267 (1993).
135. Groothuis, T. & Neefjes, J. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. Curr. Top. Microbiol. Immunol. 300, 127-148 (2005).
136. Cole, K. E. et al. Interfaron-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187, 2009-2021 (1998).
137. Farber, J. M. A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl Acad. Sci. USA 87, 5238-5242 (1990).
138. Rani, M. R. et al. Characterization of β-R1, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-α. J. Biol. Chem. 271, 22878-22884 (1996).
139. Luster, A. D., Unkeless, J. C. & Ravetch, J. V. γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315, 672-676 (1985).
140. Shi, F. D. & Van, K. L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nature Rev. Immunol. 6, 751-760 (2006).
141. Fontes, J. D., Kanazawa, S., Nekrep, N. & Peterlin, B. M. The class II transactivator CIITA is a transcriptional integrator. Microbes Infect. 1, 863-869 (1999).
142. LeibundGut-Landmann, S. et al. Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 34, 1513-1525 (2004).
143. Wright, K. L. & Ting, J. P. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27, 405-412 (2006).
144. Denzin, L. K., Hammond, C. & Cresswell, P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184, 2153-2165 (1996).
145. Denzin, L. K., Robbins, N. F., Carboy-Newcomb, C. & Cresswell, P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1, 595-606 (1994).
146. Gruneberg, U. et al. The structure and function of the novel MHC class II molecule, HLA-DM. Biochem. Soc. Trans. 25, 208S (1997).
147. Kropshofer, H., Arndt, S. O., Moldenhauer, G., Hammerling, G. J. & Vogt, A. B. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6, 293-302 (1997).
148. Morris, P. et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368, 551-554 (1994).
149. Vogt, A. B. & Kropshofer, H. HLA-DM - an endosomal and lysosomal chaperone for the immune system. Trends Biochem. Sci. 24, 150-154 (1999).
150. Kleinschmidt, W. J. & Schultz, R. M. Similarities of murine γ interferon and the lymphokine that renders macrophages cytotoxic. J. Interferon Res. 2, 291-299 (1982).
151. Blumberg, B. S. Australia antigen and the biology of hepatitis B. Science 197, 17-25 (1977).
152. Greenberg, H. B.et al. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med. 295, 517-522 (1976).
153. Weimar, W. et al. Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet 310, 1282 (1977).
154. Hoofnagle, J. H. et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 95, 1318-1325 (1988).
155. Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology 45 507-539 (2007).
156. Bertoletti, A., Maini, M. & Williams, R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res. 60, 61-66 (2003).
157. Carmen, W. et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic HBV infection. Lancet 2, 588-591 (1989).
158. Lau, G. K. et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005).
159. Marcellin, P. et al. Peginterferon affa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004).
160. Hoofnagle, J., Mullen, K. & Jones, D. Treatment of chronic nonA nonB hepatitis with recombinant human α interferon: A preliminary report. N. Engl. J. Med. 328, 465-470 (1986).
161. Choo, Q.-L. et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis clone. Science 244, 359-361 (1989).
162. Heathcote, J. & Main, J. Treatment of hepatitis C. J. Viral Hepat. 12, 223-235 (2005).
163. Foster, G. R. Past, present, and future hepatitis C treatments. Semin. Liver Dis. 24 (Suppl. 2), 97-104 (2004).
164. de Koning, E. W, van Bijsterveld, O. P. & Cantell, K. Combination therapy for dendritic keratitis with acyclovir and α-interferon. Arch. Ophthalmol. 101, 1866-1868 (1983).
165. Jones, B. R., Coster, D. J., Falcon, M. G. & Cantell, K. Topical therapy of ulcerative herpetic keratitis with human interferon. Lancet 17, 128 (1976).
166. Merigan, T C. et al. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N. Engl. J. Med. 298 981-987 (1978).
167. Pazin, G. J. et al. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N. Engl. J. Med. 301, 225-230 (1979).
168. Winston, D. J. et al. Recombinant interferon α-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am. J. Med. 85, 147-151 (1988).
169. Lui, S. F. et al. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol. Dial. Transplant. 7, 1230-1237 (1992).
170. Haglund, S., Lundquist, P. G., Cantell, K & Strander, H. Interferon therapy in juvenile laryngeal papillomatosis. Arch. Otolaryngol. 107, 327-332 (1981).
171. Pazin, G. J. et al. Effects of interferon-α on human warts. J. Interferon Res. 2, 235-243 (1982).
172. Eron, L. J. et al. Interferon therapy for condylomata acuminata. N. Engl. J. Med. 315, 1059-1064 (1986).
173. Healy, G. B. et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical Dial. N. Engl. J. Med. 319, 401-407 (1988).
174. Weck, P. K., Buddin, D. A. & Whisnant, J. K. Interferons in the treatment of genital human papillomavirus infections. Am. J. Med. 85, 159-164 (1988).
175. Deuñas, L. et al. Use of interferon-α in laryngeal papillomatosis: Eight years of the Cuban national programme. J. Laryngol. Otol. 111, 134-140 (1997).
176. Beutner, K. R. et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 42, 789-794 (1998).
177. Tyring, S. K. et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. 178, 551-555 (1998).
178. Moore, R. A., Edwards, J. E., Hopwood, J. & Hicks, D. Imiquimod for the treatment of genital warts: A quantitative systematic review. BMC Infect. Dis. 1, e3 (2001).
179. Lane, H. C. et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann. Intern. Med. 112, 805-811 (1990).
180. Krown, S. E., Aeppli, D. & Balfour, H. H. Jr. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-α2b and idovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20, 245-254 (1999).
181. Merigan, T C., Reed, S. E., Hall, T S. & Tyrrell, D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet 301, 563-567 (1973).
182. Scott, G. M. et al. Prevention of rhinovirus colds by human interferon α,2 from Escherichia coli. Lancet 320, 186-188 (1982).
183. Higgins, P. G. et al. Intranasal interferon as protection against experimental respiratory cononavinus infection in volunteers. Antimicrob. Agents Chemother. 24, 713-715(1983).
184. Treanor, J. J., Betts, R. F, Erb, S. M., Roth, F. K. & Dolin, R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J. Infect Dis. 156, 379-383 [1987).
185. Hayden, F G., Kaiser, D. L. & Albrecht, J. K. Intranasal recombinant α-2b interferon treatment of naturally occurring common colds. Antimicrob. Agents Chemother. 32, 224-230 (1988).
186. Douglas, R. M. et al. Prophylactic efficacy of intranasal α 2-interferon against rhinovinus infections in the family setting. N. Engl. J. Med. 314, 65-70 (1986).
187. Farr, B. M., Gwaltney, J. M. Jr., Adams, K. F & Hayden, F G. Intranasal interferon-α 2 for prevention of natural rhinovirus colds. Antimicrob. Agents Chemother. 6. 31-34 (1984).
188. Loutfy, M. R. et al. Interferon allacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA 290, 3222-3228 (2003).
189. Jacobs, L., O'Malley, J., Freeman, A. & Ekes, R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214, 1026-1028 (1981).
190. Knobler, R. L. et al. Systemic α-interferon therapy of multiple sclerosis. Neurology 34, 1273-1279 (1984).
191. Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Exacerbations of multiple sclerosis in patients treated with γ interferon. Lancet 329, 893-895 (1987).
192. Panitch, H. S., Hirsch, R. L., Schindler, J. & Johnson, K. P. Treatment of multiple sclerosis with γ interferon: Exacerbations associated with activation of the immune system. Neurology 37, 1097-1102 (1987).
193. IFNB MS Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661 (1993).
194. Paty, D. W. & Li, D. K. Interferon β-1 b is effective in relapsing-remitting multiple sclerosis. II. Mill analysis results ofa multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/ MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43, 662-667 (1993).
195. Bermel, R. A. & Rudick, R. A. Interferon-β treatment for multiple sclerosis. Neurotherapeutics 4, 633-646 (2007).
196. Rudick, R. A. & Cutter, G. Interferon-β for multiple sclerosis: long-term benefits? Ann. Neurol. 61, 283-285(2007).
197. Hauser, S. L. & Johnston, S. C. Recombinant therapeutics: From bench to bedside (if your health plan concurs). Ann. Neural. 60, 1OA- 11A (2006).
198. Ascherio, A. & Munger, K. L. Environmental risk factors for multiple
199. Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part II: The role of infection. Ann. Neurol. 61, 288-299 (2007).
200. Lincoln, M. R. et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nature Genet 37, 1108-1112 (2005).
201. Peltonen, L. Old suspects fiound guilty - the first genome profile of multiple sclerosis. N. Engl. J. Med. 357, 927-929 (2007).
202. Calabresi, P. A. et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann. Neurol. 41, 669-674 (1997).
203. Frank, J. A. et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann. Neurol. 36, S86-S90 (1994).
204. Stone, L. A. et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37, 611-619 (1995).
205. Shiow, L. R. et al. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540-544 (2006).
206. Stuve, O. et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann. Neurol. 40, 853-863 (1996).
207. Leppert, D., Waubant, E., Burk, M. R., Oksenberg, J. R. & Hauser, S. L. Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40, 846-852 (1996).
208. Fernald, G. H. et al. Genome-wide network analysis reveals the global properties of IFN-β immediate transcriptional effects in humans. J. Immunol. 178, 5076-5085 (2007).
209. Rudick, R. A., Lee, J. C., Simon, J., Ransoholf, R. M. & Fisher, E. Defining interferon β response status in multiple sclerosis patients. Ann. Neurol. 56, 548-555 (2004).
210. Gutterman, J. U. Cytokine therapeutics: Lessons from interferon α. Proc. Natl Acad. Sci. USA 91, 1198-1205 (1994).
211. Kurzrock, R., Talpaz, M. & Gutterman, J. U. Hairy cell leukemia: Review of treatment. Br. J. Haematol. 79 (Suppl. 1), 17-20 (1991).
212. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 92 1541-1548 (1998).
213. Talpaz, M. Interferon-α-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin. Hematol. 38, 22-27 (2001).
214. Bonifazi, F. et al. Chronic myeloid leukemia and interferon-α: A study of complete cytogenetic responders. Blood 98, 3074-3081 (2001).
215. Borden, E. C. in Cancer Medicine 7 (eds Kute, D. W. et al.) 733-743 [BC Decker, Ontario, 2006).
216. Rohatiner, A. Z. et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. Oncol. 23, 2215-2223 (2005).
217. Gresser, I., Maury, C. & Belardelli, F. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases. Int. J. Cancer 39 789-792 (1987).
218. Müller, C. R., Smeland, S., Bauer, H. C., Saeter, G. & Strander, H. Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 44, 475-480 (2005).
219. Kirkwood, J. M. et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670-1677 (2004).
220. Wheatley, K. et al. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 29, 241-252 (2003).
221. Eggermont, A. M. M. & Gore, M. Randomized adjuvant therapy trials in melanoma: Surgical and systemic trials. Semin. Oncol. 34, 507-513 (2007).
222. Weiss, K. Safety profile of interferon-α therapy. Semin. Oncol. 25, S9-S13 (1998).
223. Kirkwood, J. M. et al. Mechanisms and management of toxicities associated with high-dose interferon α-2b therapy. J. Clin. Oncol. 20, 3703-3718 (2002).
224. Diaz, M. O. et al. Deletions of interferon genes in acute lymphoblastic leukemia. N. Engl. J. Med. 322, 77-82 (1990).
225. Fountain, J. W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl Acad. Sci. USA 89 10557-10561 (1992).
226. Olopade, O. I. et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 53 (Suppl. 10), 2410-2415 (1993).
227. DeYoung, K. L. et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 15, 453-457 (1997).
228. Ding, Y, Lee, J. F., Lu, H., Lee, M. H. & Yan, D. H. Interferon-inducible protein IFIXαx1 functions as a negative regulator of HDM2. Mol. Cell Biol. 26, 1979-1996 (2006).
229. Johnsen, A., France, J., Sy M. S. & Harding, C. V. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 58, 3660-3667 (1998).
230. Shou, J. et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc. Natl Acad. Sci. USA 99, 2830-2835 (2002).
231. Seliger, B. et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9, 1721-1727 (2003).
232. Hoek, K. et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 5270-5282 (2004).
233. Pitha-Rowe, I. et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res. 64, 8109-8115 (2004).
234. Ito, N. et al. STAT3 polymorphism predicts interferon-α response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25, 2785-2791 (2007).
235. Casey, G. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature Genet. 32, 581-583 (2002).
236. Borden, E. C. Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: Potential application to melanoma. Cytokine Growth Factor Rev. 18, 491-501 (2007).
237. Nakaii, M. et al. IFN-α prevents the growth of preneoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 25, 389-397 (2004).
238. Borden, E. C., Sidky, Y. A., Ertürk, E., Wierenga, W. & Bryan, G. T. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. Cancer Res. 50, 1071-1074 (1990).
239. Kulik, L. M, Can therapy of hepatitis C affect the development of hepatocellular carcinoma? J. Natl Comp. Cancer Netw. 4, 751-757 (2006).
240. Chawla-Sarkar, M. et al. Apoptosis and intererons: Role of interferon-stimulated genes as mediators of apoptosis. Apopitosis 8, 237-249 (2003).
241. Ballestrero, A. et al. Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin. Cancer Res. 10, 1463-1470 (2004).
242. Sato, K. et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31 3138-3146 (2001).
243. Chaperot, L. et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 176, 248-255 (2006).
244. Buechner, S. A. et al. Regression of basal cell carcinoma by intralesional interferon-α treatment is mediated by CD95 (Apo-1/ Fas)-CD95ligand-induced suicide. J. Clin. Invest. 100, 2691-2696 (1997).
245. Ugurel, S. et al. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with Bcl-2 and Bcl-x expression and is sensitive to modulation by interferon-γ. Int. J Cancer 82, 727-736 (1999).
246. Schwartzberg, L. S. et al. Modulation of the Fas signaling pathway by IFN-γ in therapy of colon cancer: Phase I trial and correlative studies of IFN-γ, 5-fluorouracil, and leukovorin. Clin. Cancer. Res. 8, 2488-2498 (2002).
247. Leaman, D. W. et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 (XAF1) as an interferon-stimulated gene that augments TRAIL/Apo2L-induced apoptosis. J. Biol. Chem. 277, 28504-28511 (2002).
248. Lee, M. G. et al. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: Implication for attenuated p53 response to apoptotic stresses. Oncogene 25, 5807-5822 (2006).
249. Pizzoferrato, E. et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res. 64, 8381-8388 (2004).
250. Pfeffer, L. M. et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58, 2489-2499 (1998).
251. Tannenbaum, C. S. & Hamilton, T. A. Immune-inflammatory mechanisms in IFN-γ-mediated anti-tumor activity. Semin. Cancer Biol. 10, 113-123 (2000).
252. Glimcher, L. H., Townsend, M. J., Sullivan, B. M. & Lord, G. M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nature Rev. Immunol. 4, 900-911 (2004).
253. Mikhak, Z. et al. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. J. Immunol. 176, 4959-4967 (2006).
254. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nature Rev. Immunol. 6, 836-848 (2006).
255. Swann, J. B. et al. Type 1 IFN contributes to NK cell homeostasis, activation, and antitumor functions. J. Immunol. 178, 7540-7549 (2007).
256. Strehl, B. et al. Interferon-γ, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol. Rev. 207, 19-30 (2005).
257. Greiner, J. W. et al. Intraperitoneal administration of interferon-γ to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and cancinoembryonic antigen on malignant ascites cells. J. Clin. Oncol. 10, 735-746 (1992).
258. Folkman, J. Angiogenesis: An organizing principle for drug discovery. Nature Rev. Drug Discovery 6, 273-286 (2007).
259. Brouty-Boye, D. & Zetter, B. R. Inhibition of cell motility by interferons. Science 208, 516-518 (1980).
260. Dvorak, H. F. & Gresser, I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl Cancer Inst. 81, 497-502 (1989).
261. Sidky, Y. A. & Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47, 5155-5161 (1987).
262. Dinney, C. P. et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 58, 808-814 (1998).
263. McCarty, M. F., Bielenberg, D., Donawho, C., Bucana, C. D. & Fidler, I. J. Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin. Exp. Metastasis 19, 609-615 (2002).
264. von Marschall, Z. et al. Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl Cancer Inst. 95, 437-448 (2003).
265. Reznikov, L. L. et al. Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-α2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. J. Interferon Cytokine Res. 18, 897-903 (1998).
266. Yang, J. & Richmond, A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9, 846-855 (2004).
267. Feldman, E. D. et al. Interferon γ-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann. Surg. Oncol. 13, 125-133 (2006).
268. Guenzi, E. et al. The guanylate binding protein-1 CTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J. 22, 3772-3782 (2003).
269. Lindner, D. J. Interferons as antiangiogenic agents. Curr. Oncol. Rep. 4, 510-514 (2002).
270. Faria, A. M. et al. The nucleoporin Nup96 is required for proper expression of interferon-regulated proteins and functions. Immunity 24, 295-304 (2006).
271. Han, J. Q. & Barton, D. J. Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8, 512-525 (2002).
272. Gale, M. J. Jr et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227 (1997).
273. Carpten, J. et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genet. 30, 181-184 (2002).
274. Urisman, A. et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2, e25 (2006).
275. Dong, B. et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl Acad. Sci. USA 104, 1655-1660 (2007).
276. Pedersen, I. M. et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919-922 (2007).
277. Brideau-Andersen, A. D. et al. Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases. Proc. Natl Acad. Sci. USA 104, 8269-8274 (2007).
278. Walsh, R. J. et al. Type I interferon-inducibie gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56, 3784-3792 (2007).